New drug combo tested for tough-to-treat blood cancer
NCT ID NCT01242267
Summary
This study tested a combination of three drugs (thalidomide, bortezomib, and high-dose melphalan) alongside a patient's own stem cells for people with advanced multiple myeloma who didn't respond well to previous treatment. Researchers wanted to find the safest dose of thalidomide in this combination and see how well it controlled the cancer. The trial involved 29 participants and measured side effects, treatment response, and how long patients stayed off additional treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Conditions
Explore the condition pages connected to this study.